Hepatitis E should be considered a neglected tropical disease

Andrew S. Azman, Iza Ciglenecki, Joseph F. Wamala, Julia Lynch, Rakesh Aggarwal, Mahmudur Rahman, Sid Wong, Micaela Serafini, Ali M. Moussa, Harry R. Dalton, Ananta Shrestha, Rajendra Pant, Raquel Peck, Emily S. Gurley

1 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 2 Médecins Sans Frontières, Geneva, Switzerland, 3 World Health Organization, Juba, Republic of South Sudan, 4 International Vaccine Institute, Seoul, South Korea, 5 Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 6 Infectious Disease Division, icddr,b, Dhaka, Bangladesh, 7 Medical Department, Médecins Sans Frontières, Amsterdam, the Netherlands, 8 Chad Ministry of Health, Department of Communicable Diseases, N'Djamena, Chad, 9 Truro, Cornwall, United Kingdom, 10 Liver Foundation Nepal, Kathmandu, Nepal, 11 SAARC TB and HIV/AIDS Centre, Kathmandu, Nepal, 12 World Hepatitis Alliance, London, United Kingdom

* azman@jhu.edu

Hepatitis E virus (HEV) is a major cause of acute jaundice worldwide, with a case fatality risk (CFR) as high as 30% among symptomatic pregnant women. Human HEV includes four genotypes; the nonepidemic, zoonotic genotypes (typically 3 and 4) have gained increasing recognition in North America and Europe over the past decade [1] because of the potential risk of transmission through food, blood transfusions, and organ donation. However, relatively little attention and few resources have been invested into genotypes 1 and 2 (g1/g2), which cause outbreaks among the world’s most vulnerable populations living with poor access to safe water and sanitation infrastructure. Here, we argue that the burden of this disease, combined with the neglect by the public health, research, and clinical communities and limited options for treatment and control, make it a serious candidate for classification as a neglected tropical disease (NTD).

HEV g1/g2 are transmitted through the fecal–oral route, so large water and sanitation interventions have been implemented during outbreaks to reduce transmission. The few studies that have looked into intervention impact during outbreaks provide little evidence of major intervention-related reductions in risk, especially during outbreaks in Africa [2,3]. However, studying the effects of these interventions is difficult because of the long incubation period of the disease and relatively imprecise diagnostics and clinical case definitions [2–4]. There are no therapeutics known to reduce morbidity and mortality from acute hepatitis E in the general population, although antivirals may provide some hope in the future [5]. Fortunately, there is a vaccine licensed for use in China, Hecolin (Xiamen Innovax Biotech, China), that has demonstrated high efficacy in a large randomized trial [6]. However, this vaccine is not approved for purchase by United Nations organizations (World Health Organization [WHO] prequalified), nor has it been used in routine public health interventions.

The classification as an NTD by WHO can bring additional dedicated public health and research resources to a disease, in addition to increasing general awareness in the health community and beyond. Recent additions to this list include chromoblastomycosis and other deep mycoses, scabies and other ectoparasites, and snake bite envenoming [7]. The WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases currently lists 20 recognized NTDs and has set out the criteria that should be met for future additions to the list [6]. These criteria are as follows: (1) the condition disproportionately affects populations living in poverty...
and causes important morbidity and mortality in such populations, justifying a global response; (2) the condition primarily affects populations living in tropical and subtropical areas; (3) the condition is immediately amenable to broad control, elimination, or eradication by applying one or more of the five public health strategies adopted by the (WHO) Department for Control of NTDs; and/or (4) the condition is relatively neglected by research when it comes to developing new diagnostics, medicines, and other control tools. Here, we review these four criteria with respect to hepatitis E caused by epidemic HEV (primarily g1/g2) and provide the evidence to support its inclusion as an NTD.

**Criterion 1: The condition disproportionately affects populations living in poverty and causes important morbidity and mortality in such populations, justifying a global response**

Outbreaks of HEV g1/g2 are almost exclusively reported from countries with a low to medium human development index in Africa and Asia, with an estimated 50,000 HEV-related deaths occurring annually, mostly attributable to g1/g2 [8,9]. Vulnerable subpopulations within these countries are frequently affected, including displaced persons [2,10,11] and those living in urban slums, where water and sanitation services and health infrastructure are poor [12–14]. Pregnant women, another vulnerable subpopulation, are among those most likely to die from symptomatic disease, with a CFR of up to 30% [13,15]. Although there is limited evidence to assess the relative risk of HEV infection or mortality among persons living with HIV compared with the general population, those with advanced liver disease are known to be at increased risk for severe outcomes from HEV infections [16].

Travel-related hepatitis E (g1/g2) cases are reported in Europe and North America, although there is little evidence of onward transmission from those cases, suggestive of the critical role of water and sanitation infrastructure in reducing risk [4,17,18]. Given that HEV tends to circulate in areas where surveillance systems are weak, that the clinical case definition of hepatitis E is nonspecific, and the high proportion of mild or asymptomatic infections [8,9], global estimates of hepatitis E incidence (infection and/or disease) and mortality are poor. Our current understanding of the burden of hepatitis E g1/g2 come from three primary sources: (1) surveillance or studies related to “outbreaks,” (2) routine surveillance data from hospitals, and (3) serological studies. Two recent systematic reviews of outbreaks of HEV highlighted that outbreak size and CFR vary considerably between settings, with some outbreaks reporting tens of thousands of clinical cases and CFRs ranging from 1%–3% among the general population and from 5%–30% among pregnant women [13,15]. Even in settings with no reported hepatitis E outbreaks, seroprevalence studies have suggested the presence of ongoing transmission, with many older serologic surveys likely underestimating true seroprevalence because of insensitive diagnostics [15,19,20]. Studies in Bangladesh estimated that 9%–25% of maternal deaths are associated with acute jaundice, with hepatitis E as the likely cause of the majority of these deaths [21–23].

**Criterion 2: The condition primarily affects populations living in tropical and subtropical areas**

Reports of hepatitis E come primarily from tropical and subtropical areas, including the parts of Africa and Asia described previously [13]. Despite decades of global efforts, 30% of the world’s population still lives without consistent and adequate access to safely managed drinking water [24], and the contamination of their water with human feces puts them at risk for HEV infection. These people predominantly live in the world’s poorest countries in tropical
and subtropical areas, where surveillance systems to aid in the control of outbreaks are often inadequate.

**Criterion 3: The condition is immediately amenable to broad control, elimination, or eradication by applying one or more of the five public health strategies adopted by the Department for Control of NTDs**

The best way to prevent HEV g1/g2 transmission is through universal access to (and use of) safely managed water and sanitation, as evidenced by the lack of outbreaks in high-income settings. The populations most at risk for hepatitis E g1/g2 include some of the hardest to access, where sustainable gains in water and sanitation may be decades away. Fortunately, vaccination may provide a unique opportunity to reduce the burden of disease on both individuals and health systems. Whereas other genotypes of hepatitis E have known zoonotic reservoirs [25], g1/g2 do not, making these genotypes more plausible candidates for elimination through public health interventions.

**Criterion 4: The condition is relatively neglected by research—i.e., resource allocation is not commensurate with the magnitude of the problem—when it comes to developing new diagnostics, medicines, and other control tools**

Hepatitis E research is neglected by traditional research funders. We conducted a nonexhaustive search of recently awarded grants from three large biomedical research donors and found very few investments in hepatitis E. Although there is no perfect comparator disease, we found that compared with cholera and typhoid, two diseases that are often considered neglected, transmitted through similar pathways, and vaccine preventable, investments in HEV are relatively small (Table 1). For example, the United States National Institutes of Health invested roughly 0.6 million USD in hepatitis E research per year from 2008 to 2017, whereas during the same time period, they invested 17.3 million USD per year in cholera and 8.9 million USD per year in typhoid-related research.

Only one hepatitis E vaccine, a genotype 1 recombinant vaccine, Hecolin (Xiamen, China), has been tested in a phase III trial and was found to be safe and effective against sporadic hepatitis E genotype 4. This demonstrated cross protection, and the fact that all known genotypes belong to a single serogroup suggests the vaccine will protect across genotypes [26]. However, because of the lack of clear recommendations for when to use the vaccine [27], the lack of

| Donor                          | Average Annual Investment in Hepatitis E (USD) | Average Annual Investment in Cholera (USD) | Average Annual Investment in Typhoid (USD) | Time Period | Source                                                                 |
|-------------------------------|-----------------------------------------------|-------------------------------------------|-------------------------------------------|-------------|-----------------------------------------------------------------------|
| US National Institutes of Health | $590,000                                      | $17,390,000                               | $8,969,000                               | 2008–2017   | https://federalreporter.nih.gov/projects/search/                        |
| The Bill and Melinda Gates Foundation | $64,000                                       | $6,608,000                                | $13,573,000                              | 2010–2017   | https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database |
| Wellcome Trust*               | $0                                            | $432,000                                  | $1,085,000                               | 2005–2017   | https://wellcome.ac.uk/funding/grants-awarded                         |

*Conversion used is 1 pound = 1.27 USD.

https://doi.org/10.1371/journal.pntd.0007453.t001
WHO prequalification, and simply the lack of experience with using this vaccine, it has never been adopted within a national public health system. Heclol is currently licensed for use among nonpregnant persons aged $\geq 16$ years because of a lack of evidence in other groups, limiting the potential impact on mortality and morbidity at the individual- and population-level. Modeling results suggest that reactive vaccination against hepatitis E outbreaks may help avert significant numbers of deaths [28]; however, this has not been tested in practice and remains an important research question. We believe that well-documented experiences with this vaccine in epidemic and endemic settings will help inform more specific global policy recommendations and help countries feel more confident about adopting the use of the vaccine.

Conclusions

Hepatitis E disease caused by HEV g1/g2 has a significant burden globally, especially among the most vulnerable subtropical populations. The disease is amenable to broad control with improvements in infrastructure and vaccination programs and should be classified as an NTD. Even if the current vaccine obtains WHO prequalification, widespread use and increased investment (e.g., by GAVI, the vaccine alliance) will likely remain limited until we have better data on disease burden and disease risk and evidence to support use of the vaccine in expanded populations and settings as noted by WHO [26]. If prevention tools are readily available, then the resources for surveillance are easier to justify. If burden-of-disease data highlight key areas with elevated incidence and/or mortality, they can spur development and deployment of cost-effective interventions. As with many other NTDs, the historically limited investments in hepatitis E g1/g2 have led to this vicious cycle, in which limited tools and knowledge preclude new investments. Advances in reducing the burden of epidemic hepatitis E may be extremely difficult without investments in both defining the problem and identifying new solutions, across sectors.

Classification as an NTD alone will certainly not alleviate the suffering from this disease in the short term, but it may help break the cycle of neglect by accelerating advances in research and public health action and elevating epidemic hepatitis E in the global health agenda. Although we focused specifically on g1/g2, this level of specificity may make it harder to communicate, and there may be benefits for focusing on all genotypes of hepatitis E, especially because we know little about the burden and distribution of genotypes 3 and 4 in lower-income countries. With the recent release of “Recommendations to assure the quality, safety and efficacy of recombinant hepatitis E vaccines” (http://www.who.int/biologicals/expert_committee/POST_ECBS_2018_Recommendations_HEP_E_vaccines.pdf?ua=1), a clear pathway for prequalification of hepatitis E vaccines exists, and we urge rapid progress so that this valuable tool can easily be used by countries experiencing hepatitis E outbreaks. We also urge donors to invest in research ranging from basic science to studies of transmission to the development of interventions and testing of effective intervention strategies. Finally, we advocate for discussions within WHO and with countries affected by HEV g1/g2 to further develop the case for classification as an NTD.

References

1. Kupferschmidt K. Europe’s new hepatitis problem. Science. 2016; 353: 862–863. https://doi.org/10.1126/science.353.6302.862 PMID: 27563081
2. Guthmann J-P, Kloostad H, Boccia D, Hamid N, Pinoges L, Nizou J-Y, et al. A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clinical Infectious Diseases. 2006; 42: 1685–1691. https://doi.org/10.1086/504321 PMID: 16705572
3. Spina A, Beversluis D, Irwin A, Chen A, Nassariman JN, Ahamat A, et al. Learning from water treatment and hygiene interventions in response to a hepatitis E outbreak in an open setting in Chad. Journal of Water and Health. 2018; 16: 223–232. https://doi.org/10.2166/wh.2018.258 PMID: 29676798
4. Azman AS, Ciglenecki I, Oeser C, Said B, Tedder RS, Ijaz S. The incubation period of hepatitis E genotype 1: insights from pooled analyses of travellers. Epidemiol Infect. 2018; 70: 1–4. https://doi.org/10.1017/S0950268818001097

5. Netzler NE, Tuipulotu DE, Vasudevan SG, Mackenzie JM, White PA. Antiviral candidates for treating hepatitis E virus infection. Antimicrob Agents Chemother. 2019. https://doi.org/10.1128/AAC.00003-19 PMID: 30885901

6. Zhang J, Zhang X-F, Huang S-J, Wu T, Hu Y-M, Wang Z-Z, et al. Long-Term Efficacy of a Hepatitis E Vaccine. N Engl J Med. 2015; 372: 914–922. https://doi.org/10.1056/NEJma1406011 PMID: 25738667

7. World Health Organization [Internet]. Geneva, Switzerland: World Health Organization; 2019 [cited 2019 Apr 24]. Neglected Tropical Diseases. Available from: http://www.who.int/neglected_diseases/diseases/en/

8. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The Lancet. https://doi.org/10.1016/S0140-6736(16)30579-7 PMID: 27394647

9. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012; 55: 988–997. https://doi.org/10.1002/hep.25505 PMID: 22121109

10. Vernieri L, Lenglet A, Hogema BM, Moussa AM, Ariti C, Vollmer S, et al. Seroprevalence and risk factors of recent infection with hepatitis E virus during an acute outbreak in an urban setting in Chad, 2017. BMC Infect Dis. 2018; 18: 287. https://doi.org/10.1186/s12879-018-3194-6 PMID: 29940939

11. Browne LB, Menkir Z, Kahi V, Maina G, Asnakew S, Tubman M, et al. Notes from the field: hepatitis E outbreak among refugees from South Sudan-Gambella, Ethiopia, April 2014-January 2015. MMWR Morb Mortal Wkly Rep. 2015; 64: 537. PMID: 25996097

12. Gurley ES, Hossain MJ, Paul RC, Sazzad HMS, Islam MS, Parveen S, et al. Outbreak of hepatitis E in urban Bangladesh resulting in maternal and perinatal mortality. Clin Infect Dis. 2014. https://doi.org/10.1093/cid/ciu383 PMID: 24855146

13. Hakim MS, Wang W, Bramer WM, Geng J, Huang F, de Man RA, et al. Global burden of hepatitis E outbreaks: a systematic review. Liver Int. 2016; 37: 19–31. https://doi.org/10.1111/liv.13237 PMID: 27542764

14. World Health Organization [Internet]. Geneva, Switzerland: World Health Organization; Jan 2018 [cited 2019 Apr 23]. Hepatitis E—Namibia. Available from: http://www.who.int/csr/don/15-january-2018-hepatitis-e-namibia/en/

15. Kim J-H, Nelson KE, Panzner U, Kasture Y, Labrique AB, Wierzba TF. A systematic review of the epidemiology of hepatitis E virus in Africa. BMC Infect Dis. 2014; 14: 308. https://doi.org/10.1186/1471-2334-14-308 PMID: 24902967

16. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014; 27: 116–138. https://doi.org/10.1128/CMR.00057-13 PMID: 24396139

17. Pischke S, Schulze-Zur-Wiesch J, Lütgehetmann M, Kreuels B, Lueth S, Kapaun P, et al. High clinical manifestation rate in an imported outbreak of hepatitis E genotype 1 infection in a German group of travellers returning from India. Ann Hepatol. 2017; 16: 57–62. https://doi.org/10.5604/16652681.1226815

18. Roberts JK, Whitlock RT. Hepatitis E in a Traveler to Bangladesh. Ann Intern Med. 1992; 117: 93–93. https://doi.org/10.7326/0003-4819-117-1-93_1 PMID: 1596057

19. Azman AS, Bouhenia M, Iyer AS, Rumunu J, Laku RL, Wamala JF, et al. High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan. Am J Trop Med Hyg. 2017; 96: 1296–1301. https://doi.org/10.4269/ajtmh.16-0620 PMID: 28719276

20. Kmush BL, Labrique AB, Dalton HR, Ahmed ZB, Ticehurst J, Heaney CD, et al. Two Generations of “Gold Standards”: The Impact of a Decade in Hepatitis E Virus Testing Innovation on Population Seroprevalence. Am J Trop Med Hyg. 2015; 93: 15–0159–717. https://doi.org/10.4269/ajtmh.15-0159 PMID: 26149865

21. Labrique AB, Sikder SS, Krain LJ, Heaney CD, Rashid M, et al. Hepatitis E, a vaccine-preventable cause of maternal deaths. Emerg Infect Dis. 2012; 18: 1401–1404. https://doi.org/10.3201/eid1809.120241 PMID: 22931753

22. Shah R, Nahar Q, Gurley ES. One in Five Maternal Deaths in Bangladesh Associated with Acute Jaundice: Results from a National Maternal Mortality Survey. Am J Trop Med Hyg. 2016; 94: 695–697. https://doi.org/10.4269/ajtmh.15-0662 PMID: 26755563

23. Gurley ES, Halder AK, Streetfield PK, Sazzad HMS, Huda TMN, Hossain MJ, et al. Estimating the Burden of Maternal and Neonatal Deaths Associated With Jaundice in Bangladesh: Possible Role of
Hepatitis E Infection. Am J Public Health. 2012; 102: 2248–2254. https://doi.org/10.2105/AJPH.2012.300749 PMID: 23078501

24. World Health Organization and UNICEF [Internet]. Joint Monitoring Program. [cited 2019 Apr 1]. Available from: www.washdata.org/data.

25. Nan Y, Wu C, Zhao Q, Zhou E-M. Zoonotic Hepatitis E Virus: An Ignored Risk for Public Health. Front Microbiol. 2017; 8: 1900. https://doi.org/10.3389/fmicb.2017.01900

26. Zhu F-C, Zhang J, Zhang X-F, Zhou C, Wang Z-Z, Huang S-J, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. The Lancet. 2010; 376: 895–902. https://doi.org/10.1016/S0140-6736(10)61030-6

27. World Health Organization. Hepatitis E vaccine: WHO position paper, May 2015—Recommendations. Vaccine. 2016; 34: 304–305. https://doi.org/10.1016/j.vaccine.2015.07.056 PMID: 26232546

28. Ben S Cooper, White LJ, Siddiqui R. Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: A modelling study. PLoS Negl Trop Dis. 2018; 12: e0006807. https://doi.org/10.1371/journal.pntd.0006807 PMID: 30252843